Dyslipidemia Fact Sheet in Korea, 2022
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Objective: This study aimed to investigate the prevalence and status of dyslipidemia management among South Korean adults, as performed by the Korean Society of Lipid and Atherosclerosis under the name Dyslipidemia Fact Sheet 2022. Methods: We analyzed the lipid profiles, age-standardized and crude prevalence, management status of hypercholesterolemia and dyslipidemia, and health behaviors among Korean adults aged ≥20 years, using the Korea National Health and Nutrition Examination Survey data between 2007 and 2020. Results: In South Korea, the crude prevalence of hypercholesterolemia (total cholesterol ≥240 mg/dL or use of a lipid-lowering drug) in 2020 was 24%, and the age-standardized prevalence of hypercholesterolemia more than doubled from 2007 to 2020. The crude treatment rate was 55.2%, and the control rate was 47.7%. The crude prevalence of dyslipidemia (more than one out of three conditions [low-density lipoprotein-cholesterol ≥160 or the use of a lipid-lowering drug, triglycerides ≥200, or high-density lipoprotein-cholesterol (men and women) <40 mg/dL]) was 40.2% between 2016 and 2020. However, it increased to 48.2% when the definition of hypo-high-density lipoprotein-cholesterolemia in women changed from <40 to <50 mg/dL. Conclusion: Although the prevalence of hypercholesterolemia and dyslipidemia has steadily increased in South Korea, the treatment rate remains low. Therefore, continuous efforts are needed to manage dyslipidemia through cooperation between the national healthcare system, patients, and healthcare providers.
Abstract
Objective: This study aimed to investigate the prevalence and status of dyslipidemia management among South Korean adults, as performed by the Korean Society of Lipid and Atherosclerosis under the name Dyslipidemia Fact Sheet 2022. Methods: We analyzed the lipid profiles, age-standardized and crude prevalence, management status of hypercholesterolemia and dyslipidemia, and health behaviors among Korean adults aged ≥20 years, using the Korea National Health and Nutrition Examination Survey data between 2007 and 2020. Results: In South Korea, the crude prevalence of hypercholesterolemia (total cholesterol ≥240 mg/dL or use of a lipid-lowering drug) in 2020 was 24%, and the age-standardized prevalence of hypercholesterolemia more than doubled from 2007 to 2020. The crude treatment rate was 55.2%, and the control rate was 47.7%. The crude prevalence of dyslipidemia (more than one out of three conditions [low-density lipoprotein-cholesterol ≥160 or the use of a lipid-lowering drug, triglycerides ≥200, or high-density lipoprotein-cholesterol (men and women) <40 mg/dL]) was 40.2% between 2016 and 2020. However, it increased to 48.2% when the definition of hypo-high-density lipoprotein-cholesterolemia in women changed from <40 to <50 mg/dL. Conclusion: Although the prevalence of hypercholesterolemia and dyslipidemia has steadily increased in South Korea, the treatment rate remains low. Therefore, continuous efforts are needed to manage dyslipidemia through cooperation between the national healthcare system, patients, and healthcare providers.
참고문헌 (14)
- 이은정, "2018 Guidelines for the Management of Dyslipidemia in Korea", 지질·동맥경화학회지, 8(2), pp.78~131 (2019), 한국지질동맥경화학회[DOI]
- "Fact sheets: cardiovascular diseases (CVDs)" (2021)[URL]
- 조소미, "Dyslipidemia Fact Sheets in Korea 2020: an Analysis of Nationwide Population-based Data", 지질·동맥경화학회지, 10(2), pp.202~209 (2021), 한국지질동맥경화학회[DOI]
- Kweon S, "Data resource profile : the Korea National Health and Nutrition Examination Survey(KNHANES)", Int J Epidemiol, 43, pp.69~77 (2014)
- Friedewald WT, "Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge", Clin Chem, 18, pp.499~502 (1972)
- 서미혜, "2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea", Journal of Obesity & Metabolic Syndrome, 28(1), pp.40~45 (2019), 대한비만학회[DOI]
- Yun Sungha, "Development of the Korean Healthy Eating Index for adults, based on the Korea National Health and Nutrition Examination Survey", Nutrition Research and Practice, 16(2), pp.233~247 (2022), 한국영양학회[DOI]
- Mach F, "2019 ESC", EAS Guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk, 2020, pp.41, 111~188
- 양예슬, "Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement", Diabetes and Metabolism Journal, 47(1), pp.1~9 (2023), 대한당뇨병학회[DOI]
- 양예슬, "Obesity Fact Sheet in Korea, 2021: Trends in Obesity Prevalence and Obesity-Related Comorbidity Incidence Stratified by Age from 2009 to 2019", Journal of Obesity & Metabolic Syndrome, 31(2), pp.169~177 (2022), 대한비만학회
- Wilson PW, "The metabolic syndrome : a practical guide to origins and treatment : part II", Circulation, 108, pp.1537~1540 (2003)
- Williams CM, "Lipid metabolism in women", Proc Nutr Soc, 63, pp.153~160 (2004)
- 허규연, "2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association", Diabetes and Metabolism Journal, 45(4), pp.461~481 (2021), 대한당뇨병학회[DOI]
- Lingvay I, "Obesity management as a primary treatment goal for type 2 diabetes : time to reframe the conversation", Lancet, 399, pp.394~405 (2022)